Metastatic Hepatocellular Carcinoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

Also known as: Hepatocellular Carcinoma Metastatic / Metastatic hepatocellular carcinoma (morphologic abnormality) / Hepatocellular carcinoma / Carcinoma hepatocellular / Hepatoma / Primary carcinoma of liver (disorder) / Liver carcinoma / (Liver carcinoma) or (Ca: [liver/biliary system] or [biliary system]) / Carcinoma liver / Liver cell carcinoma (disorder) / Hepatocellular carcinoma (morphologic abnormality) / Carcinoma of liver / Carcinoma, Hepatocellular

IndicationStatusPhase
DBCOND0041971 (Metastatic Hepatocellular Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05168163Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerTreatment
NCT04511455Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line TreatmentTreatment